Compare Globus Medical Inc. Class A Common Stock (GMED) vs TTM Technologies Inc. Common Stock (TTMI) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

TTMI trades at $116.10, up 5.23% today, but faces a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong revenue growth is projected, from $2.9B in 2025 to $3.4B in 2026, alongside a rising net profit margin. A significant $1.7B defense backlog and expansion in AI data-center demand support the growth narrative, though the stock's valuation multiples appear elevated.

The outlook is mixed; robust fundamentals and overwhelming analyst buy ratings (85.7%) suggest long-term potential, with a consensus price target of $203.67 implying substantial upside. However, near-term technical weakness and high valuation ratios relative to profitability metrics present risks, requiring careful monitoring of execution against growth expectations.